Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Detection of BRCA1, BRCA2, and ATM Alterations in Matched Tumor Tissue and Circulating Tumor DNA in Patients with Prostate Cancer Screened in PROfound
Kim N., Alan Barnicle, Caroline Sibilla, et al.
Clinical Cancer Research (2022) Vol. 29, Iss. 1, pp. 81-91
Open Access | Times Cited: 41

Showing 1-25 of 41 citing articles:

Prostate cancer and liquid biopsies: Clinical applications and challenges
Fumihiko Urabe, Takayuki Sumiyoshi, Kojiro Tashiro, et al.
International Journal of Urology (2024) Vol. 31, Iss. 6, pp. 617-626
Open Access | Times Cited: 7
BRCA-deficient metastatic prostate cancer has an adverse prognosis and distinct genomic phenotype
Heidi Fettke, Chao Dai, Edmond M. Kwan, et al.
EBioMedicine (2023) Vol. 95, pp. 104738-104738
Open Access | Times Cited: 19
Combining PARP Inhibitors and Androgen Receptor Signalling Inhibitors in Metastatic Prostate Cancer: A Quantitative Synthesis and Meta-analysis
Carlo Messina, Emilio Francesco Giunta, Alessio Signori, et al.
European Urology Oncology (2023) Vol. 7, Iss. 2, pp. 179-188
Open Access | Times Cited: 18
Efficacy and safety of PARP inhibitors in metastatic castration-resistant prostate cancer: A systematic review and meta-analysis of clinical trials
Giovanni Maria Iannantuono, Elias Chandran, Charalampos S. Floudas, et al.
Cancer Treatment Reviews (2023) Vol. 120, pp. 102623-102623
Open Access | Times Cited: 17
Prostate cancer genotyping for risk stratification and precision treatment
Ashish Kumar
Current Urology (2024) Vol. 18, Iss. 2, pp. 87-97
Open Access | Times Cited: 5
BRCA Mutation Testing in Men with Metastatic Castration‐Resistant Prostate Cancer: Practical Guidance for Australian Clinical Practice
Arun Azad, Howard Gurney, Ainsley Campbell, et al.
Asia-Pacific Journal of Clinical Oncology (2025)
Open Access
Decoding driver and phenotypic genes in cancer: Unveiling the essence behind the phenomenon
Dequan Liu, Lei Liu, Xiaoman Zhang, et al.
Molecular Aspects of Medicine (2025) Vol. 103, pp. 101358-101358
Open Access
First-line combination treatment with PARP and androgen receptor–signaling inhibitors in HRR-deficient mCRPC: Applying clinical study findings to clinical practice in the United States
Rana R. McKay, Alicia K. Morgans, Neal D. Shore, et al.
Cancer Treatment Reviews (2024) Vol. 126, pp. 102726-102726
Open Access | Times Cited: 4
Germline and somatic testing for homologous repair deficiency in patients with prostate cancer (part 1 of 2)
Andrew J. Armstrong, Amy K. Taylor, Michael Haffner, et al.
Prostate Cancer and Prostatic Diseases (2024)
Open Access | Times Cited: 4
NGS-basierte („next generation sequencing“) molekulare Panelanalyse des metastasierten Prostatakarzinoms: Wie häufig finden wir therapierbare Mutationen?
Olivia Steenbock, Pia Paffenholz, Constantin Rieger, et al.
Deleted Journal (2025)
Open Access
Towards clinical implementation of circulating tumor DNA in metastatic prostate cancer: Opportunities for integration and pitfalls to interpretation
Edmond M. Kwan, Alexander W. Wyatt, Kim N.
Frontiers in Oncology (2022) Vol. 12
Open Access | Times Cited: 21
Feasibility of Next-generation Sequencing of Liquid Biopsy (Circulating Tumor DNA) Samples and Tumor Tissue from Patients with Metastatic Prostate Cancer in a Real-world Clinical Setting in Germany
Philipp Mandel, Benedikt Hoeh, Clara Humke, et al.
European Urology Focus (2024) Vol. 10, Iss. 2, pp. 339-345
Open Access | Times Cited: 3
Genomic profiling and clinical utility of circulating tumor DNA in metastatic prostate cancer: SCRUM-Japan MONSTAR SCREEN project
Masaki Shiota, Nobuaki Matsubara, Taigo Kato, et al.
BJC Reports (2024) Vol. 2, Iss. 1
Open Access | Times Cited: 2
Diagnostics and treatment of BRCA-associated cancers with olaparib — expert position statement
Artur Kowalik, Anita Chudecka-Głaz, Joanna Kufel-Grabowska, et al.
Oncology in Clinical Practice (2024) Vol. 20, Iss. 4, pp. 229-244
Open Access | Times Cited: 2
Circulating Tumor DNA in Genitourinary Cancers: Detection, Prognostics, and Therapeutic Implications
Margo B. Gerke, Caroline S. Jansen, Mehmet Asim Bilen
Cancers (2024) Vol. 16, Iss. 12, pp. 2280-2280
Open Access | Times Cited: 2
Preservation of cfRNA in cytological supernatants for cfDNA & cfRNA double detection in non‐small cell lung cancer patients
Yidan Ma, Yifei Wang, Lei He, et al.
Cancer Medicine (2024) Vol. 13, Iss. 17
Open Access | Times Cited: 2
Plasma ctDNA as a treatment response biomarker in metastatic cancers: evaluation by the RECIST working group
Alexander W. Wyatt, Saskia Litière, François‐Clément Bidard, et al.
Clinical Cancer Research (2024) Vol. 30, Iss. 22, pp. 5034-5041
Closed Access | Times Cited: 2
PARP inhibitors for prostate cancer
Ossian Longoria-Lozano, Nick Beije, Johann S. de Bono
Seminars in Oncology (2023) Vol. 51, Iss. 1-2, pp. 25-35
Open Access | Times Cited: 6
Practical Guidance on Establishing a Molecular Testing Pathway for Alterations in Homologous Recombination Repair Genes in Clinical Practice for Patients with Metastatic Prostate Cancer
Martin Schostak, Angela R. Bradbury, Alberto Briganti, et al.
European Urology Oncology (2023) Vol. 7, Iss. 3, pp. 344-354
Open Access | Times Cited: 5
Roles of the PARP Inhibitor in BRCA1 and BRCA2 Pathogenic Mutated Metastatic Prostate Cancer: Direct Functions and Modification of the Tumor Microenvironment
Takahiro Inoue, Sho Sekito, Takumi Kageyama, et al.
Cancers (2023) Vol. 15, Iss. 9, pp. 2662-2662
Open Access | Times Cited: 5
Therapeutic biomarkers in metastatic castration-resistant prostate cancer: does the state matter?
Peter H. J. Slootbeek, Sofie H. Tolmeijer, Niven Mehra, et al.
Critical Reviews in Clinical Laboratory Sciences (2023) Vol. 61, Iss. 3, pp. 178-204
Open Access | Times Cited: 5
Predictive and prognostic biomarkers in urological tumours
Alessia Cimadamore, Carmine Franzese, Carla Di Loreto, et al.
Pathology (2023) Vol. 56, Iss. 2, pp. 228-238
Open Access | Times Cited: 5
Circulating Biomarkers Predictive of Treatment Response in Patients with Hormone-sensitive or Castration-resistant Metastatic Prostate Cancer: A Systematic Review
Michaël Baboudjian, Arthur Peyrottes, Charles Dariane, et al.
European Urology Oncology (2024) Vol. 7, Iss. 6, pp. 1228-1245
Closed Access | Times Cited: 1
Decoding the Dynamics of Circulating Tumor DNA in Liquid Biopsies
Khadija Shahab Turabi, Kelsey Klute, Prakash Radhakrishnan
Cancers (2024) Vol. 16, Iss. 13, pp. 2432-2432
Open Access | Times Cited: 1
Durable benefit from poly(ADP-ribose) polymerase inhibitors in metastatic prostate cancer in routine practice: biomarker associations and implications for optimal clinical next-generation sequencing testing
Daniel Triner, Ryon P. Graf, Russell W. Madison, et al.
ESMO Open (2024) Vol. 9, Iss. 9, pp. 103684-103684
Open Access | Times Cited: 1
Page 1 - Next Page

Scroll to top